Multimorbidity and comorbidity in psoriatic arthritis – a perspective

Lubrano, Ennio; Scriffignano, Silvia; Perrotta, Fabio Massimo

doi:10.1080/1744666x.2021.1825941

Cited by 19 publications

(18 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As an interesting aspect, this review showed that the prevalence and impact of medical comorbidity on patient-reported outcomes (PROs) were very high in patients with PsA, while no data were found on the impact of comorbidity on composite indices. However, our results confirmed that FM and anxiety should be considered in the management of PsA patients for their potential impact, trying to identify these two as multi-morbidities more than comorbidities [5].…”

Section: Discussionsupporting

confidence: 72%

“…Of the studied population, 92 (63.8%) were male, the mean (SD) age was 56.6 (± 13.4) years and the median (IQR range) disease duration was 10 (4.5-17) years. DAPSA median (IQR range) was 8.4 (4.3-16), PsAID median was 2.2 (0.8-4), HAQ-DI median was 0.25 (0-0.75), and PtGA median was 3 (2)(3)(4)(5)(6). The patients that satisfied MDA 5/7 criteria were 75 (52%).…”

Section: Resultsmentioning

confidence: 99%

“…Beyond the musculoskeletal and skin involvement, PsA is associated with extra-articular manifestations and comorbidities that might increase the burden of the disease [4,5]. PsA, together with the broad group of spondyloarthritis, is frequently associated with comorbidities and, based on some studies, more than half of PsA patients were affected by at least one comorbidity [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study

et al. 2020

Self Cite

View full text Add to dashboard Cite

Introduction The aim of this study was to evaluate the impact of comorbidities on disease activity, patient’s impact of the disease, patient global assessment, and function in psoriatic arthritis (PsA). Methods Consecutive PsA patients were enrolled in this cross-sectional study. During the visit, the patients underwent a complete physical examination and clinical/laboratory data were collected, including type and number of comorbidities, recorded as simple comorbidity count (SCC). Disease activity was assessed using the Disease Activity Score for Psoriatic Arthritis (DAPSA) and the Minimal Disease Activity (MDA) was also evaluated. The Psoriatic Arthritis Impact of Disease (PsAID), the Health Assessment Questionnaire-Disability Index (HAQ-DI), and the Patient Global Assessment of disease activity (PtGA) were also collected. Results A total of 144 patients were enrolled. At least one comorbidity was registered in 104 (72.2%) patients. The SCC was associated with DAPSA ( β = 1.48, p = 0.013), PsAID ( β = 0.41, p < 0.01), HAQ-DI ( β = 0.11, p < 0.01) and PtGA ( β = 0.50, p < 0.01). The comorbidities that showed an impact on outcome measures were anxiety and fibromyalgia (FM). Anxiety showed an impact on DAPSA ( β = 14.46, p < 0.001), PsAID ( β = 1.98, p = 0.039) and HAQ-DI ( β = 0.54, p = 0.036). FM showed an impact on DAPSA ( β = 6.46, p = 0.025), PsAID ( β = 2.88, p < 0.001), HAQ-DI ( β = 0.70, p < 0.001), PtGA ( β = 2.00, p = 0.014), and MDA ( β = − 2.79, p = 0.01). The median PtGA value was different among patients with different numbers of comorbidities . Conclusions This study showed that comorbidities, either as a simple comorbidity count number or as single comorbidity, might have an impact on the main domains affecting PsA patients in real clinical practice.

show abstract

Section: Discussionsupporting

confidence: 72%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the brother (A) with the most erosive form, the molecular profiling highlights the overexpression of genes strictly related to inflammation and immunomodulatory processes but also associates with PsA comorbidities, such as cardiovascular and metabolic. 16 Moreover, the presence of one disease (arthritis) within another (psoriasis, cardiovascular, metabolic, gastrointestinal) and relative severity degree may modify the molecular and clinical expression of either condition.…”

Section: Discussionmentioning

confidence: 99%

Gene Expression Profiling of Monozygotic Twins Affected by Psoriatic Arthritis

Angioni

Floris

Cangemi

et al. 2021

OARRR

View full text Add to dashboard Cite

“…Psoriatic arthritis (PsA) is a complex inflammatory disease in which different cutaneous, musculoskeletal, extra-articular manifestations and comorbidities come together to define the clinical phenotype [1]. The hallmark of articular manifestations is the presence of arthritis (both peripheral and axial), dactylitis and enthesitis, with a possible association with extra-articular manifestations and comorbidities, leading the physician to take a ''holistic'' approach when treating patients [2]. In recent years, PsA treatment has rapidly evolved with the introduction of new biologics and small-molecule drugs, and the aim of treatment is to induce remission or low disease activity in all disease domains [3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

New Insights in Physical Therapy and Rehabilitation in Psoriatic Arthritis: A Review

et al. 2021

Self Cite

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) is a complex, multiform and chronic inflammatory disease characterized by the association of psoriasis and arthritis with other musculoskeletal and extra-articular manifestations. The treatment of PsA is rapidly evolving due to the introduction of new biologic and small-molecule drugs, and the aim of treatment is to induce a condition of remission or low disease activity in all disease domains. However, unmet treatment needs still persist for those patients with impaired function, reduced quality of life or comorbidities. In this context, physical therapy and rehabilitation could provide additional benefits by reducing disease activity and improving function. Although a large number of studies have assessed the role of physical therapy and exercise in other forms of chronic inflammatory arthritis, such as axial spondyloarthritis and rheumatoid arthritis, evidence on their effect on persons with PsA is still lacking. However, some studies have reported the potential positive role of physical therapy on the different disease domains of PsA, in helping to improve disease activity, prevent or improve articular impairment, improve pain management and improve quality of life. Here, we review current evidence on physical therapy, exercise and rehabilitation in patients with PsA. In particular, we review the literature focusing on each domain, to provide evidence of efficacy and effectiveness of exercise and rehabilitation on skin, peripheral arthritis, axial involvement, dactylitis, enthesitis and comorbidities.

show abstract

Multimorbidity and comorbidity in psoriatic arthritis – a perspective

Cited by 19 publications

References 72 publications

Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study

Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study

Gene Expression Profiling of Monozygotic Twins Affected by Psoriatic Arthritis

New Insights in Physical Therapy and Rehabilitation in Psoriatic Arthritis: A Review

Contact Info

Product

Resources

About